Open access
Sep 2026
Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study.
Not available.
Mathieu Meunier, S. Thepot, Stanislas Nimubona et al.
· Haematologica · 0 citations